Comparative Pharmacology
Head-to-head clinical analysis: DEXASPORIN versus DEXTENZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXASPORIN versus DEXTENZA.
DEXASPORIN vs DEXTENZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexasporin is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties. It binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of pro-inflammatory mediators such as prostaglandins and leukotrienes.
Dexamethasone is a corticosteroid with glucocorticoid activity that binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as prostaglandins and leukotrienes, and suppression of immune cell migration and activation.
1 to 2 mg/kg intramuscular or intravenous every 8 hours.
Insert 0.4 mg intracanalicularly (into the lacrimal punctum) as a single dose; releases dexamethasone over 30 days.
None Documented
None Documented
3-4 hours (prolonged to 10-15 hours in renal impairment; monitor CrCl <30 mL/min)
The terminal elimination half-life of dexamethasone from plasma after systemic absorption is approximately 3-4 hours. However, Dextenza provides sustained local delivery to the ocular surface; the insert releases dexamethasone over 30 days, with therapeutic levels maintained throughout.
Renal excretion (80-90% unchanged), biliary/fecal (10-20%)
Dextenza (dexamethasone ophthalmic insert) is administered intracanalicularly; systemic absorption is minimal. Following release into the tear film, the drug is primarily eliminated via nasolacrimal drainage and subsequent gastrointestinal absorption with hepatic metabolism. Renal excretion accounts for <5% of the dose as unchanged drug; biliary/fecal elimination is negligible.
Category C
Category C
Corticosteroid/Antibiotic Combination
Corticosteroid